Systematic Literature Reviews for the Medical Device Industry
A Cost-Effective Way to Strengthen Your Product’s Evidence Base
Recent news and posts
Updates in coverage recommendations for CGM devices in type 2 diabetes in Sweden
On May 8, 2025, the Medical Technologies Product (MTP) Council issued an updated recommendation on the use of continuous glucose monitoring (CGM) for patients with type 2 diabetes (T2D) within the Orderly Introduction of Medical Technologies framework. In Sweden, the term “continuous glucose monitoring” encompasses both flash glucose monitoring (FGM) and CGM devices.
The Orderly Introduction of Medical Technologies framework is a staged process, including horizon scanning, selection of the method for evaluation, the decision on national collaboration, health economic evaluation by the Dental and Pharmaceutical Benefits Agency (TLV), and recommendations by the MTP Council to Swedish regions.
In 2022, the MTP Council recommended two products - FreeStyle Libre and FreeStyle Libre 2 - for T2D patients meeting specific clinical criteria. Since then, more CGM devices have entered the market. In May 2025, the MTP Council revised its recommendations to allow the use of other CGM devices deemed equivalent to FreeStyle Libre and FreeStyle Libre 2. An equivalent product is defined as a CGM system that delivers the same function and effect and does not exceed the total cost of the previously recommended products. Regarding the clinical criteria, the recommendations remain.
At the same time, the MTP Council decided to reassess CGM devices for T2D patients and tasked TLV to conduct a new health economic evaluation.
While TLV’s reassessment is underway, the updated 2025 recommendations remain in effect.
See the full details in Swedish here and here.
This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.